Indivior (INDV) Q2 EPS Jumps 104%

Indivior (NASDAQ:INDV) significantly exceeded Q2 2025 analyst expectations, reporting non-GAAP EPS of $0.51 against a $0.25 consensus and GAAP revenue of $302 million, surpassing the $241.67 million forecast, primarily driven by a 9% year-over-year increase in U.S. SUBLOCADE net revenue to $195 million. Citing strong first-half results, management raised its full-year fiscal 2025 revenue guidance to $1,030-$1,080 million and adjusted EBITDA guidance to $275-$300 million. The positive performance comes despite higher marketing expenses and continued generic competition for legacy products, with the company also noting its recent exclusive Nasdaq listing and Russell index inclusion.

Analysis

Indivior reported a significant outperformance for Q2 2025, with non-GAAP EPS of $0.51 more than doubling the $0.25 analyst consensus. This was driven by GAAP revenue of $302 million, which handily beat the $241.67 million forecast, though it represented a modest 1.0% year-over-year increase. The primary growth engine remains SUBLOCADE, whose U.S. net revenue grew 9% year-over-year to $195 million, a gain fueled by volume rather than price increases. While this growth is robust, it came at the cost of increased marketing spend, which pushed non-GAAP SG&A expenses up 7% and caused adjusted EBITDA to decline 5.4% to $88 million. The company's legacy SUBOXONE Film franchise showed resilience, with stabilizing prices slowing its revenue decline. Bolstered by this strong performance, management raised its full-year fiscal 2025 guidance for both net revenue to $1,030–$1,080 million and adjusted EBITDA to $275–$300 million. Corporate developments, including an exclusive Nasdaq listing and inclusion in Russell indexes, may improve stock visibility, while a solid cash position of $538 million provides liquidity to navigate ongoing litigation liabilities and competitive pressures.

Key Decisions for Investors

• Given the substantial earnings beat and upwardly revised full-year guidance, investors should assess if the market has fully priced in the strong growth trajectory of SUBLOCADE.
• It is critical to monitor the trade-off between SUBLOCADE's revenue growth and the associated increase in marketing expenses, as this dynamic directly impacts adjusted EBITDA margins and overall profitability.
• Consider the potential for increased institutional ownership and trading liquidity following the company's exclusive Nasdaq listing and inclusion in the Russell 2000 and 3000 indexes.
• Key risks to watch include the pace of generic erosion on the legacy SUBOXONE business and any material developments concerning the company's significant litigation-related liabilities.